Author

Gregory Sebastien Ronel

Columbia University Irving Medical Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Albert HungiD· 1 shared Chloe A PaolucciiD· 1 shared David A. BakeriD· 1 shared Denys OliinykiD· 1 shared Domenico AcciliiD· 1 shared Elisabeth Zollbrecht· 1 shared Elizabeth M. RheaiD· 1 shared Eunhee ChoiiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Albert HungORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Reprogramming insulin receptor activation with a de novo agonist to overcome severe insulin resistance

Albert Hung, Xinru Wang, Michael Gao, Michelle Ng, Denys Oliinyk, Riley R. Weaver, Elisabeth Zollbrecht, Sarah Caixeta Cardoso, Gregory Sebastien Ronel, Chloe A Paolucci, Jianxiang Ye, Qing Fan, Elizabeth M. Rhea, Matthias Mann, David A. Baker, , Eunhee Choi

This study develops a de novo insulin receptor agonist, RF-409, which effectively treats severe insulin resistance in a mouse model by activating a mutant receptor and improving glucose homeostasis.

bioRxiv · May 7, 2026 · PreprintPharmacology & Toxicology